Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III first-line anti-EGFR chimeric monoclonal antibody trial in RAS/BRAF wild-type metastatic colorectal cancer
CTR20170701Phase 3Active
- Sponsor
- Shanghai Zhangjiang Biotechnology
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of cetuximab in colorectal cancer (CRC), sponsored by Shanghai Zhangjiang Biotechnology. Started Jan 2018; status: active.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20170701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170701.